Secretory Leukocyte Protease Inhibitor (SLPI) Delays Development of Murine Squamous Cell Carcinoma and Inhibits Metastasis. W Jin, J Wen, MF Starost, G McGrady, SD Shapiro and SM Wahl, OIIB, NIDCR, NIH, and DVR, NIH, Bethesda, MD and Univ Pittsburg, Pittsburg, PA. (101.33)

Wenwen Jin,Jie Wen,Matthew Starost,George McGrady,Steven Shapiro,Sharon Wahl

DOI: https://doi.org/10.4049/jimmunol.184.supp.101.33

2010-01-01

Abstract:Abstract Development of squamous cell carcinomas (SCC) represents a multistage process of transformation, invasion and metastasis dependent on genetic aberrancies and contributions of surrounding stroma. Dissemination to distant sites depends on proteolytic enzymes to enable migration and entry into vessels, underscored by a protease-protease inhibitor imbalance. Deletion of SLPI, a serine protease inhibitor expressed in most epithelia, which potently inhibits elastase, is linked to altered tumor progression. In rodents, SLPI is also generated by inflammatory cells, and has antimicrobial and anti-inflammatory activities, in addition to inhibition of proteases. To establish which of these functions are critical in regulating tumorigenesis, we chemically induced SCC in SLPI null and wildtype mice and monitored skin tumor progression, invasion and lung metastasis. In the absence of SLPI, increased inflammatory infiltrates in pre-malignant skin tissues along with more evident protease accumulation was associated with earlier papilloma development, but malignant transformation from the papilloma, once formed, to SCC was similar in null and wildtype mice. Subsequent tumor cell invasion and metastasis to the lungs was significantly enhanced in the absence of SLPI. Resetting the balance of protease-protease inhibitor through deletion of elastase (elastase null) abrogated tumorigenesis, suggesting that elastase promotes tumor progression if unopposed by its endogenous inhibitor, SLPI.